Stiris Research Inc. Announces the First Site Initiated in a Phase II Trial in Chronic Kidney disease

Cambridge, MA — June 4, 2024 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiated in a Phase II Chronic Kidney Disease (CKD) study.

“We are thrilled to announce the activation of the first site in this complement-mediated kidney disease study. The study is now open to recruitment and screening of subjects. We are proud to be supporting this Sponsor in their effort to bring targeted treatment to this patient population and look forward to continued collaborations ahead” said Shantal Feltham, President & CEO.

Kidney disease can affect your body’s ability to clean your blood, filter extra water out of your blood, and help control your blood pressure. It can also affect red blood cell production and vitamin D metabolism. Our kidneys are very adaptable. They can compensate for some of the problems that can happen when you have kidney disease, in fact your symptoms will reveal themselves slowly over time. You may not feel symptoms until your disease is advanced. When your kidneys are damaged, waste products and fluid can build up in your body. That can cause swelling in your ankles, nausea, weakness, poor sleep, and shortness of breath. Without treatment, the damage can get worse and your kidneys may eventually stop working.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.